Compare QMLS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QMLS | CHRS |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.4M | 177.7M |
| IPO Year | 2025 | 2014 |
| Metric | QMLS | CHRS |
|---|---|---|
| Price | $5.79 | $1.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 352.2K | ★ 1.3M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.31 | $1.09 |
| 52 Week High | $14.82 | $2.62 |
| Indicator | QMLS | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 32.85 | 50.32 |
| Support Level | $5.52 | $1.34 |
| Resistance Level | $7.72 | $1.46 |
| Average True Range (ATR) | 0.71 | 0.09 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 13.91 | 70.00 |
QumulusAI Inc is a cloud infrastructure company engaged in the rapid deployment of graphics processing unit (GPU)-powered solutions for artificial intelligence (AI) applications, serving a critical market that is often overlooked by large-scale cloud providers (hyperscalers), which operate massive, standardized computing infrastructures serving the immense enterprises. The platform delivers flexible, competitively priced, and customizable solutions for underserved small- and mid-market customers, including machine learning teams, AI infrastructure startups, and research institutions, and also supports the scale and complexity requirements of large enterprises. Its products are B300 SXM6, B200 SXM, RTX Pro 6000, H200 SXM, and Others. Its solutions are Enterprise, Research, and AI Startups.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.